相似文献
1
Hypoxia: a barricade to conquer the pancreatic cancer.
Cell Mol Life Sci. 2020 Aug;77(16):3077-3083. doi: 10.1007/s00018-019-03444-3. Epub 2020 Jan 6.
2
Targeting hypoxic tumor microenvironment in pancreatic cancer.
J Hematol Oncol. 2021 Jan 13;14(1):14. doi: 10.1186/s13045-020-01030-w.
3
Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.
Cancer Lett. 2020 Nov 1;492:63-70. doi: 10.1016/j.canlet.2020.07.041. Epub 2020 Aug 18.
4
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters.
Pancreatology. 2017 Jan-Feb;17(1):7-12. doi: 10.1016/j.pan.2016.12.010. Epub 2016 Dec 23.
5
The role of hypoxia in pancreatic cancer: a potential therapeutic target?
Expert Rev Gastroenterol Hepatol. 2016;10(3):301-16. doi: 10.1586/17474124.2016.1117386. Epub 2015 Nov 27.
6
Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers.
Cancer Lett. 2023 Sep 1;571:216345. doi: 10.1016/j.canlet.2023.216345. Epub 2023 Aug 7.
7
Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer.
Curr Pharm Des. 2012;18(17):2395-403. doi: 10.2174/13816128112092395.
8
Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology.
Cancer Lett. 2017 Apr 28;392:83-93. doi: 10.1016/j.canlet.2017.01.041. Epub 2017 Feb 8.
9
A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts.
Anticancer Agents Med Chem. 2012 Sep;12(7):791-800. doi: 10.2174/187152012802650264.
10
Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments.
Recent Pat Anticancer Drug Discov. 2018;13(4):455-468. doi: 10.2174/1574892813666180831102519.
引用本文的文献
1
Thermoresponsive NDP hydrogel embedded with MnO nanoparticles for postoperative antirecurrence therapy in pancreatic cancer.
Sci Rep. 2025 Jul 2;15(1):23570. doi: 10.1038/s41598-025-08431-2.
2
Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer.
PLoS One. 2025 May 2;20(5):e0322618. doi: 10.1371/journal.pone.0322618. eCollection 2025.
3
The role of LncRNA-MANCR induced by HIF-1α drive the malignant progression of pancreatic cancer by targeting miRNA-494/SIRT1 signaling axis under hypoxic conditions.
Cancer Gene Ther. 2025 Apr 7. doi: 10.1038/s41417-025-00900-0.
4
Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.
Sci Adv. 2025 Mar 14;11(11):eadq4416. doi: 10.1126/sciadv.adq4416. Epub 2025 Mar 12.
5
Redox regulation: mechanisms, biology and therapeutic targets in diseases.
Signal Transduct Target Ther. 2025 Mar 7;10(1):72. doi: 10.1038/s41392-024-02095-6.
6
The Mechanism and Latest Progress of m6A Methylation in the Progression of Pancreatic Cancer.
Int J Biol Sci. 2025 Jan 13;21(3):1187-1201. doi: 10.7150/ijbs.104407. eCollection 2025.
7
Investigating the effects of stereotactic body radiation therapy on pancreatic tumor hypoxia and microvasculature in an orthotopic mouse model using intravital fluorescence microscopy.
Sci Rep. 2024 Dec 28;14(1):31348. doi: 10.1038/s41598-024-82757-1.
8
Role of the mA demethylase ALKBH5 in gastrointestinal tract cancer (Review).
Int J Mol Med. 2025 Feb;55(2). doi: 10.3892/ijmm.2024.5463. Epub 2024 Nov 29.
9
Hypoxia-related bioinformatic signatures associated with prognosis and tumor microenvironment of pancreatic cancer: Current status, concerns, and future perspectives.
World J Gastroenterol. 2024 Nov 28;30(44):4689-4696. doi: 10.3748/wjg.v30.i44.4689.
10
Establishment of a Prognostic Model for Pancreatic Cancer Based on Hypoxia-Related Genes.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241288687. doi: 10.1177/15330338241288687.
本文引用的文献
1
Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
Mol Biol Rep. 2019 Dec;46(6):6629-6645. doi: 10.1007/s11033-019-05058-1. Epub 2019 Sep 5.
2
The enhancement of glycolysis regulates pancreatic cancer metastasis.
Cell Mol Life Sci. 2020 Jan;77(2):305-321. doi: 10.1007/s00018-019-03278-z. Epub 2019 Aug 20.
3
EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells.
Cancers (Basel). 2019 Aug 8;11(8):1136. doi: 10.3390/cancers11081136.
4
ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells.
Am J Transl Res. 2019 Jul 15;11(7):4470-4480. eCollection 2019.
5
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review.
Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. doi: 10.1177/1758835919850367. eCollection 2019.
6
Triptolide and Its Derivatives as Cancer Therapies.
Trends Pharmacol Sci. 2019 May;40(5):327-341. doi: 10.1016/j.tips.2019.03.002. Epub 2019 Apr 8.
7
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Int J Cancer. 2019 Sep 15;145(6):1529-1537. doi: 10.1002/ijc.32227. Epub 2019 Mar 19.
8
Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway.
Redox Biol. 2019 Apr;22:101131. doi: 10.1016/j.redox.2019.101131. Epub 2019 Jan 30.
9
Long noncoding RNA FEZF1-AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR-142/HIF-1α and miR-133a/EGFR upon hypoxia/normoxia.
J Cell Physiol. 2019 Sep;234(9):15407-15419. doi: 10.1002/jcp.28188. Epub 2019 Jan 28.
10
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis.
Mol Cancer. 2019 Jan 21;18(1):14. doi: 10.1186/s12943-018-0927-5.
Zotero 插件